Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Detalles Bibliográficos
Autores principales: Ryan, C., Guenther, L., Foley, P., Weisman, J., Burge, R.T., Gallo, G., See, K., McKean‐Matthews, M., Bertram, C.C., Merola, J.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299771/
https://www.ncbi.nlm.nih.gov/pubmed/34812561
http://dx.doi.org/10.1111/jdv.17836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299771/
https://www.ncbi.nlm.nih.gov/pubmed/34812561
http://dx.doi.org/10.1111/jdv.17836

Ejemplares similares